Current perspective of neuroprotection and glaucoma

Kailin Tian,1,2 Shannon Shibata-Germanos,1 Milena Pahlitzsch,1 M Francesca Cordeiro1,3 1Glaucoma and Retinal Neurodegeneration Research Group, UCL Institute of Ophthalmology, London, UK; 2Eye Centre, Renmin Hospital of Wuhan University, Wuhan, People’s Republic of China; 3Western Eye Hosp...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tian K, Shibata-Germanos S, Pahlitzsch M, Cordeiro MF
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/a488c007d52545829d538b4a1b41dc62
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a488c007d52545829d538b4a1b41dc62
record_format	dspace
spelling	oai:doaj.org-article:a488c007d52545829d538b4a1b41dc622021-12-02T00:43:22ZCurrent perspective of neuroprotection and glaucoma1177-5483https://doaj.org/article/a488c007d52545829d538b4a1b41dc622015-11-01T00:00:00Zhttps://www.dovepress.com/current-perspective-of-neuroprotection-and-glaucoma-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Kailin Tian,1,2 Shannon Shibata-Germanos,1 Milena Pahlitzsch,1 M Francesca Cordeiro1,3 1Glaucoma and Retinal Neurodegeneration Research Group, UCL Institute of Ophthalmology, London, UK; 2Eye Centre, Renmin Hospital of Wuhan University, Wuhan, People’s Republic of China; 3Western Eye Hospital, ICORG, Imperial College NHS Trust, London, UK Abstract: Glaucoma is the second leading cause of blindness worldwide and is most notably characterized by progressive optic nerve atrophy and advancing loss of retinal ganglion cells (RGCs). The main concomitant factor is the elevated intraocular pressure (IOP). Existing treatments are focused generally on lowering IOP. However, both RGC loss and optic nerve atrophy can independently occur with IOP at normal levels. In recent years, there has been substantial progress in the development of neuroprotective therapies for glaucoma in order to restore vital visual function. The present review intends to offer a brief insight into conventional glaucoma treatments and discuss exciting current developments of mostly preclinical data in novel neuroprotective strategies for glaucoma that include recent advances in noninvasive diagnostics going beyond IOP maintenance for an enhanced global view. Such strategies now target RGC loss and optic nerve damage, opening a critical therapeutic window for preventative monitoring and treatment. Keywords: glaucoma, retinal ganglion cell, neuroprotectionTian KShibata-Germanos SPahlitzsch MCordeiro MFDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2015, Iss default, Pp 2109-2118 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Tian K Shibata-Germanos S Pahlitzsch M Cordeiro MF Current perspective of neuroprotection and glaucoma
description	Kailin Tian,1,2 Shannon Shibata-Germanos,1 Milena Pahlitzsch,1 M Francesca Cordeiro1,3 1Glaucoma and Retinal Neurodegeneration Research Group, UCL Institute of Ophthalmology, London, UK; 2Eye Centre, Renmin Hospital of Wuhan University, Wuhan, People’s Republic of China; 3Western Eye Hospital, ICORG, Imperial College NHS Trust, London, UK Abstract: Glaucoma is the second leading cause of blindness worldwide and is most notably characterized by progressive optic nerve atrophy and advancing loss of retinal ganglion cells (RGCs). The main concomitant factor is the elevated intraocular pressure (IOP). Existing treatments are focused generally on lowering IOP. However, both RGC loss and optic nerve atrophy can independently occur with IOP at normal levels. In recent years, there has been substantial progress in the development of neuroprotective therapies for glaucoma in order to restore vital visual function. The present review intends to offer a brief insight into conventional glaucoma treatments and discuss exciting current developments of mostly preclinical data in novel neuroprotective strategies for glaucoma that include recent advances in noninvasive diagnostics going beyond IOP maintenance for an enhanced global view. Such strategies now target RGC loss and optic nerve damage, opening a critical therapeutic window for preventative monitoring and treatment. Keywords: glaucoma, retinal ganglion cell, neuroprotection
format	article
author	Tian K Shibata-Germanos S Pahlitzsch M Cordeiro MF
author_facet	Tian K Shibata-Germanos S Pahlitzsch M Cordeiro MF
author_sort	Tian K
title	Current perspective of neuroprotection and glaucoma
title_short	Current perspective of neuroprotection and glaucoma
title_full	Current perspective of neuroprotection and glaucoma
title_fullStr	Current perspective of neuroprotection and glaucoma
title_full_unstemmed	Current perspective of neuroprotection and glaucoma
title_sort	current perspective of neuroprotection and glaucoma
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/a488c007d52545829d538b4a1b41dc62
work_keys_str_mv	AT tiank currentperspectiveofneuroprotectionandglaucoma AT shibatagermanoss currentperspectiveofneuroprotectionandglaucoma AT pahlitzschm currentperspectiveofneuroprotectionandglaucoma AT cordeiromf currentperspectiveofneuroprotectionandglaucoma
_version_	1718403516392800256

Current perspective of neuroprotection and glaucoma

Ejemplares similares